Member Info for PM2022

Well I have information that indicates it is not the case.

The deal is very much on.

Also legally you would have to have an announcement if it failed. The deadline was just for due diligence so if that passed you move onto the next stages with all the legal work and approvals.

Not sure why you are still deramping 3 years on and still twisting everything. I don't get the agenda if you have no intention to buy.

EUDA roaring ahead. They obviously think the merger will be complete. Up 9% already and has been going consistently.

201 is important because it gives a higher share price and more money and extends the cash runway considerably therefore giving a better chance we get another deal. The lower the share price and the more you have to raise then the more the dilution. You don't want to increase the cash burn if we are where we are so again it has to be balanced.

Strategy changes according to the situation. I agree the performance of the BOD has been poor in regards to execution but we should wait until the outcome of 201 to see if it completes before we decide what happens next . Otherwise just a waste of time imo. If it fails then changes if not then we see how things progress with additional news/ lab contracts etc.

That is the issue. Once it goes through the evaluation stage you then have to fund the compounds therefore 201 deal or CLX deal is required or at least a higher share price in the next year. Bringing lots in and increasing costs further down the line is wrong and would show a complete lack of understanding until they deliver so they have to pace it out.

We are not 4D you have to balance the pipeline according to the share price and spend. Raising a few million at 15/20p is fine but not here. Therefore having about 2 quality projects a year is fine until the SP goes higher or until they deliver. Otherwise you would likely be left requiring large funding for lots of projects 1 or 2 years down the line.

Bad,

I would suggest it is for working capital purposes. Had you bothered to read the broker report then you would have known the cash was running very low but the question was the placing price. As I said a few days before we had a leak. Predicting 1p/2p placing, no support at all or a prediction of placing every month is not right.

BOD have paid the price with no cheap options. They need to deliver and get the SP back to something at least decent. Making more changes will mean more time wasted with notices, new staff attempting to understand the pipeline and likely more funding if the strategy changes.

You don't want too many compounds in the pipeline when the share price is this low. The key for now is to get the SP so 201 delivery, CLX news or lab contracts.

Porky the SP was stable around 40p and hit the highs of 65p when LOI was signed so at 5p it was never a fair price. You only say that because you are deramping. We may have almost double the amount of shares now but also a lab and CLX and other new compounds plus cash in the bank so really we should be considerably higher at the moment. Over time I expect a big rerate once 201 is signed soon.

Val is not based just on 201. Positive news on CLX, 301 or a few lab contracts and we can double here quite easily. I don't see the logic of people thinking 201 will not get signed as no news means the merger is progressing and if it was not we would have heard.

Anyway I ignore all the noise here because clearly it is all to suit an agenda.

It dropped significantly about 1 week before the placing. TP clients were informed at least a few days beforehand so a leak clearly happened somewhere. I have never seen such a large volume of selling for sometime in this stock.

She was pushed out I know that as a fact so don't get why you put a negative spin on every situation. That had nothing to do with 201. Been the same type of posts for the 3 years but yet you still post with no intention of ever investing. What people don't understand is that even if BOD changes were made you would simply twist something else.

I don't see the logic of spending 3/4 months attempting to complete a merger when you say it is completely dead so therefore I am convinced it will complete successfully and Valirx will get the payments. You have your agenda but the facts indicate otherwise.

The only reason the 6p placing came at the price was due to a leak after the 401 deal that is a fact we all saw the selling leading to the placing. Therefore your 1p placing prediction was again way off the mark.

If my memory is correct Stella joined when Valirx was 10p. Now if 201 happens and Valirx goes to 15/20p or more she would leave on a high and it would be a success on paper.

Now they mutually allow her to stay through the notice period because they believe 201 will happen during that time and so a rise in the SP.

The indications are all pointing to 201 completing soon. Previous news indicates plenty of shortlists for lab contracts.

They have it all to prove but let us see how it plays out. In the longer run if they get it right then 130 million shares is not much at all on AIM.

Lots of bullying and intimidation by certain individuals to try and get on the BOD to serve what i believe is a personal agenda which I do not support given a clear lack of knowledge and understanding of AIM.

The issue here is that most shareholders just follow, they don't know how to say no.

The placing is irrelevant in this case as it was for such a small amount relative to the market cap. It was probably taken by those who know the upside and what is to come so I doubt we would get any selling until after significant news.

All good and hope to add in the next few weeks.

Well handled placing.

This surely means significant cash is on the way in fact almost certain with minimal dilution.

They should now get a really decent valuation for Satoshipay in the coming weeks with money potentially being returned to us, likely more than the market cap.

Dynasty news not far away. I can see us getting back to 0.30 soon.

It is about 130/140k not 160k but never mind. They were clearly hoping to get options but that never happened.

It is irrelevant as whoever takes over will take the same wage or more that is if you are going for experience. What matters is the performance so for me I am happy to wait until the end of the month to see if the merger completes. If it completes and more cash is on the way then we will recover in the medium term. If not then it would be a good opportunity to make a change or two.

Ok thanks. They were paid a bonus that year but not since. Base salary £126k.

I think she should have invested more but then if she has a mortgage, nursery costs and other expenditure after tax how much does she really save. Is she a single parent? I don't think it says anything about the investment as she has about 600k shares already not a massive amount but still.

OK thanks.

Porky can you prove she earns over £160k plus benefits please?

Just curious to see if this is a fact or your standard de-ramp/fiction?

For that VAL would have had to deliberately lie to the market if they were only prepared to sign the sub-license once the funding for the next phase of trials was completed at the end of 2023. Based on the previous RNS's that is my interpretation.

Also what would be the point of signing a sub-license if they had no money for the trials. It seems once the merger goes through the sub-license will get signed then Val gets the agreed cash. It is that simple. Facts based on the RNS.

The sub-license contains provisions for upfront and early-stage milestone payment and will release the immediate payment for work already conducted under the previously announced service agreement as well as a commitment for future service provision.

It is facts from a published article a few months back. I used it because he used the word COULD but still they seem to think it is the case.

Digging Deeper: EUDA Health was founded in 2019 in Singapore as a technology-based provider of healthcare services. It went public on the Nasdaq last year using a special purpose acquisition company (SPAC). EUDA said TheoremRx has access to a “robust pipeline of compounds” to treat various medical conditions. TheoremRx Chairman Dr. Kenneth Sorensen added that his company’s treatments under development have an addressable market of $16 billion, and that some could be ready for commercialization as soon as the second half of next year. The two companies signed a letter of intent on Oct. 4, and have 30 days after that to negotiate a final agreement.

Next year being this year as that was printed last year.